CogniMS: observational study to assess cognition in patients with earl
CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What it measured
Main measures
Observational study, observation period 6 months
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: Patient selection and observation: This observational study focuses on patients with relapsing-remitting MS diagnosed within the last 2 years (according to McDonald or Poser criteria), who have started treatment with Betaferon during the last 6 months. The prescription of the medicine is clearly separated from the decision to include the patient in the study. The patients will be screened for cognitive changes, depression, HrQoL and fatigue every 6 months for 2 years. Patients are either newly recruited for CogniMS or have previously participated in the CogniCIS study until they have fulfilled diagnostic criteria for MS. Exclusion: See Inclusion Criteria.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To obtain observational data on cognitive deficit in MS and to elucidate whether cognitive function can predict the course of MS. To further validate the Faces Symbol Test (FST) and MS Neuropsychological Questionnaire(MSNQ) in a multinational setting. To study the interaction between cognition, depression, fatique and Health-related Qality of Life (HrQoL) in MS patients. To gather observational data on Betaferon adherence, safety and effectivity.
Loading reviews and guidelines…
History
Started
Feb 2006